MiMedx Group, Inc. (MiMedx) is an integrated developer, manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Company’s biomaterial platform technologies include AmnioFix and EpiFix that are processed from human amniotic membrane that is derived from the donated placentas. MiMedx process the human amniotic membrane utilizing its Purion Process to produce a safe and effective implant. MiMedx is the supplier of amniotic tissue, having supplied hundreds of thousands of allografts for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare. The Company’s CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process. The technology is licensed from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.